3iconcept medical solution

Regulatory approval in Europe demands precision. You deal with strict frameworks, multiple authorities, and detailed documentation. If you work with combination products, the path gets more complex. You handle both medicinal and device elements in one product. Each part follows its own rules, yet both must align. This guide breaks the process into clear steps. You learn what to prepare, where delays happen, and how to move faster with fewer errors. Understanding combination products in Europe A combination product joins a medical device and a medicinal substance into a single product. The classification depends on the product’s main mode of action. If the device drives the main effect, the product follows the Medical Device Regulation. If the medicinal part drives the effect, pharmaceutical rules apply. This classification step matters. It decides your regulatory route, timelines, and required data. In Europe, notified bodies review device components. Competent authorities review medic...

Getting approval for combination products takes time and planning. These products mix a drug and a device into one solution. Regulators review both parts with strict rules. Many companies face delays because they miss key steps early. You need a clear plan from day one. You also need strong documentation and a clear regulatory path. This guide explains the common problems and how you fix them. Understanding the Regulatory Path One major issue starts with product classification. Authorities decide if your product follows medical device rules, drug rules, or both. This decision affects your entire approval process. You need to: Identify the primary mode of action Confirm if the drug or device drives the main function Align your product with the right regulatory framework If you choose the wrong path, you face delays and extra costs. Early consultation with experts reduces this risk. Lack of Clear Documentation Poor documentation slows down approval. Regulators expect detailed technical f...

Europe maintains strict regulatory control over drug device combination products. Manufacturers who plan market entry in the European Union face a detailed review process. One major step involves evaluation from a Notified Body. This process confirms device safety, performance, and regulatory compliance before market authorization. Preparation plays a major role in approval success. Companies who plan early, organize technical documentation, and follow regulatory guidelines reduce delays during evaluation. Understanding the Regulatory Requirement Drug device combination products contain two components. A medicinal substance and a medical device work together in a single product. The European regulatory system evaluates both parts to protect patient safety. Under the European Medical Device Regulation (EU MDR 2017/745), manufacturers must submit documentation when a device includes a medicinal substance. Authorities review how the device interacts with the drug and how the product perfo...

Medical device manufacturers who plan entry into the European market must follow strict regulatory pathways. The European Union Medical Device Regulation introduced stronger oversight, improved safety standards, and detailed evaluation processes. These changes aim to protect patient health and maintain transparency across the healthcare sector. Companies developing combination products or devices that include medicinal substances face additional regulatory scrutiny. Manufacturers must demonstrate product safety, clinical effectiveness, and regulatory alignment before receiving market authorization. One key element within this process involves consultation with regulatory authorities and expert evaluation through structured assessment procedures. Understanding EU MDR Compliance Requirements EU MDR established a comprehensive regulatory framework that replaced the previous Medical Device Directive. The regulation focuses on stronger clinical evidence, improved traceability, and clearer r...